Open an account

Axsome Therapeutics

AXSM · NASDAQ

$159.58+$3.77 (+2.42%)TodayMarket closed ·
Prev close $155.81

About AXSM

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 925 full-time employees. The company went IPO on 2015-11-19. The firm focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. The company is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.

Employees
925
Headquarters
New York City, New York
Listed
Nov 19, 2015
Sector
Health Care
Industry
Pharmaceuticals
Website
axsome.com

AXSM key statistics

Market cap
8.16B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
882.91K
Volume
396.02K
Open price
$157.65
High today
$164.79
Low today
$157.38
52 Week high
$260.19
52 Week low
$123.50

Axsome Therapeutics (AXSM) at a glance

Axsome Therapeutics (AXSM) last traded at $159.58, with a market cap of 8.16B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $157.38 and $164.79. The current price is 1.4% above the day's low and 3.2% below its high.

Volume so far is 396.02K shares, below the average of 882.91K shares a day.

Over the past year Axsome Therapeutics has ranged from $123.50 to $260.19, and now sits 26% of the way up that range.

Axsome Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.99 per share against an estimate of -$0.8616.

The average analyst price target is $288.17, 80.6% above the current price, from 17 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

94%of 17 analyst ratings say Buy
  • Buy94.1%
  • Hold5.9%
  • Sell0.0%
Price target · 23 analystsAvg $288.17
Low
$248.46
Now
$159.58
High
$399.00

AXSM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 12.0% on average.

  1. Q3 FY24: reported -$1.34 per share against an estimate of -$1.44
  2. Q4 FY24: reported -$1.54 per share against an estimate of -$1.04
  3. Q1 FY25: reported -$1.22 per share against an estimate of -$1.35
  4. Q2 FY25: reported -$0.97 per share against an estimate of -$1.12
  5. Q3 FY25: reported -$0.94 per share against an estimate of -$0.8829
  6. Q4 FY25: reported -$0.56 per share against an estimate of -$0.6826
  7. Q1 FY26: reported -$1.26 per share against an estimate of -$0.9139
  8. Q2 FY26: reported -$0.99 per share against an estimate of -$0.8616

AXSM news

  • Chandrima Sanyal

    Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach

  • 10 Health Care Stocks Whale Activity In Today’s Session

  • Avi Kapoor

    5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

  • 9 Health Care Stocks Whale Activity In Today’s Session

  • Axsome Therapeutics Q1 2026 Earnings Call: Complete Transcript

  • Vandana Singh

    Strong Drug Sales Lift Axsome Revenue, But Profit Miss Drags Stock

  • Vandana Singh

    Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression

  • Press releaseGlobe Newswire

    Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader

Similar companies

Companies in the same industry as Axsome Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.